Sight Sciences to Showcase OMNI Surgical System's Long-Term Efficacy at AGS 2025

Sight Sciences, Inc. (Nasdaq: SGHT), a leading eyecare technology company, is set to present comprehensive clinical data on its OMNI® Surgical System at the 2025 American Glaucoma Society (AGS) Annual Meeting. The meeting, scheduled for February 26 to March 1, 2025, in Washington, D.C., will provide a platform for Sight Sciences to highlight the long-term safety and effectiveness of the OMNI Surgical System across diverse patient populations and disease severities.

The OMNI Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated for canaloplasty (the microcatheterization and viscodilation of Schlemm’s canal) followed by trabeculotomy (the cutting of trabecular meshwork) to reduce intraocular pressure (IOP) in adult patients with primary open-angle glaucoma (POAG). The system enables an implant-free, ab interno MIGS procedure intended to restore aqueous outflow of glaucomatous eyes by addressing the three areas of outflow resistance associated with glaucoma.

At the AGS 2025 Annual Meeting, Sight Sciences will present multiple presentations showcasing new data on the clinical effectiveness and safety of the OMNI Surgical System. These presentations will feature data curated by Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD). The data stems from a partnership between Verana Health and the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), which is one of the largest specialty society clinical data registries in all of medicine and the first comprehensive eye disease clinical registry in the United States.

One of the key presentations, titled "Systematic Review and Meta-analysis of Clinical, Economic, and Humanistic Evidence for the Canaloplasty/Trabeculotomy Surgical System (CTSS) in Open-Angle Glaucoma Treatment," will be presented by Sameh Mosaed, MD, UC Irvine. This meta-analysis of 22 unique studies, including 2,379 eyes, concluded that OMNI and predecessor devices (CTSS) consistently reduced intraocular pressure ("IOP") and decreased the need for medication up to 36 months. The data also showed that both standalone and combined treatment effectively reduced IOP and medication use for up to 24 months.

Another presentation, titled "What's your sign? GEMINI," will be given by Mona Kaleem, MD, Johns Hopkins School of Medicine. This presentation will recognize the prospective GEMINI study as a landmark trial in glaucoma, demonstrating the safety and efficacy of the OMNI Surgical System in treating primary open-angle glaucoma in adult patients.

A third presentation, titled "Standalone Canaloplasty and Trabeculotomy Outcomes for Phakic and Pseudophakic Eyes: An American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight)" will be presented by Leon W. Herndon Jr., MD, Duke University. This study, based on real-world data from the IRIS Registry, will provide valuable insights into the performance of the OMNI Surgical System across diverse patient populations and disease severities.

The breadth of clinical data presented at AGS highlights the long-term safety and effectiveness of the OMNI Surgical System in a wide range of glaucoma patients, including diverse patient populations and different disease severities. These new findings reflect Sight Sciences' commitment to advancing glaucoma care and providing physicians with effective treatment options that ultimately benefit patients by reducing their dependence on medications and improving their quality of life.

In conclusion, the upcoming AGS 2025 Annual Meeting presents an excellent opportunity for Sight Sciences to showcase the long-term efficacy and safety of the OMNI Surgical System. The company's commitment to advancing glaucoma care and providing effective treatment options for patients is evident in the comprehensive clinical data it will present at the meeting. Investors and healthcare professionals alike should pay close attention to these developments, as they may have significant implications for the future of glaucoma treatment.